Countervail Corporation


Countervail competes and is selected for participation in the SBIR sponsored Commercialization Acceleration Program (CAP).

As described by the National Institute of Health’s Small Business Innovative Research Program, today’s dynamic marketplace in the human life sciences and healthcare requires that companies focus on identifying and connecting with key customers, articulate the highest and best use of their innovative solutions and build sustainable pathways to revenue and continuing relevance.

With these in mind, the NIH Commercialization Accelerator Program (CAP), offered annually since 2004 (previously known as the Commercialization Assistance Program), is designed to help some of the agency’s most promising small life science and healthcare Phase II grantees develop their commercial businesses and transition their SBIR/STTR-funded technologies into the marketplace. Applicants are selected via a competitive process for a limited number of slots in the program.

Funded by NIH and managed through a contract with Larta, Inc. of Los Angeles, CA, the CAP provides selected participants with individualized assistance toward accomplishing key commercialization goals. This is achieved through individual mentoring and consulting sessions, training workshops, access to domain experts and focus on outcomes designed to enhance the commercialization profile and readiness of participating grantees.

Countervail Corporation is pleased to have been selected to participate in this program.